Anticoagulant therapy and components of the metabolic syndrome in patients with atrial fibrillation in real outpatient clinical practice

Abstract

The aim of the study was to determine the prevalence of atrial fibrillation (AF) in patients hospitalized in the therapeutic and cardiology departments of the St. Petersburg hospital, and to analyze the prevalence of the number of components of the metabolic syndrome (MS) in patients with AF and anticoagulant therapy (ACT) assigned to outpatient stage to hospitalization. A retrospective analysis of 1760 case histories of patients hospitalized in the therapeutic and cardiology departments of the Therapy Clinic of the Faculty of Pavlov State Medical University named after IP Pavlov for 2017 was performed. It was established that AF was found in 16.5% (286) patients hospitalized in 2017. Among the causes of AF in patients, the number of components of MS was analyzed: 0 – 2.1% (6), 1 – 4.5% (13), 2 – 19.2% (55), 3 – 34.3% (98), 4 – 31.5% (90), 5 – 8.4% (24), thus MS with 3 or more components installed in 74.1% (212) surveyed in 2017. 58.7% (168) received ACT at the time of hospitalization, and 41.3% did not receive it (118). In 32,9% of patients with AF did not receive anticoagulant therapy at the prehospital stage, with no contraindications for administration. Among patients receiving ACT at the time of hospitalization, direct oral anticoagulants were prescribed 2 times more often than warfarin (69% and 31%, р = 0,01).

Keywords

• atrial fibrillation
• metabolic syndrome
• anticoagulant therapy